13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q4 2024. See the latest, Q2 2026 →

Reported value

$1.72B

−6.8% on the quarter before

Positions

0 new · 2 sold out

Top 10

92.9%

of the value

Est. gain

+$84.3M

on stocks held all quarter

Est. return

+5.2%

on those stocks since Q3 2024

Filed

Feb 7, 2025

On SEC EDGAR ↗

Positions as of Dec 31, 2024, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2024. Striped tiles are options.

Gitlab Inc20%

Freshworks Inc15%

Arm Holdings Plc14%

Revolution Medicines Inc11%

CrowdStrike8.5%

Planet Labs Pbc7.5%

UiPath5.2%

Dexcom Inc4.7%

Verve Therapeutics Inc4.1%

Tempus AI3.0%

Prime Medicine Inc2.6%

0.7%

0.6%

0.5%

Gitlab Inc20%

Freshworks Inc15%

Arm Holdings Plc14%

Revolution Medicines Inc11%

CrowdStrike8.5%

Planet Labs Pbc7.5%

UiPath5.2%

Dexcom Inc4.7%

Verve Therapeutics Inc4.1%

Tempus AI3.0%

Prime Medicine Inc2.6%

0.7%

0.6%

0.5%

Largest buys

Since Q3 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

No buys this quarter.

Largest sells

Since Q3 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Gitlab Inc~$206.6MCut · 27.3% → 20.0%−3,667,095 shares
Snowflake~$13.2MSold out · 0.7% → 0.0%−114,554 shares
Revolution Medicines Inc~$5.4MCut · 10.5% → 10.5%−122,898 shares
Rapt Therapeutics Inc~$1.1MSold out · 0.1% → 0.0%−540,270 shares

Holdings

As of Dec 31, 2024. Changes are in shares against Sep 30, 2024, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Gitlab IncCLASS A COM · shares −38% · price +9.3%	20.0%	27.3%	$343.2M	6.1M	−38%	$56.35	$51.54	+9.3%	+$29.3M
2	Freshworks IncCLASS A COM · shares 0% · price +40.9%	15.3%	10.1%	$262.1M	16.2M	0%	$16.17	$11.48	+40.9%	+$76.0M
3	Arm Holdings PlcSPONSORED ADS · shares 0% · price −13.7%	14.1%	15.2%	$241.9M	2.0M	0%	$123.36	$143.01	−13.7%	−$38.5M
4	Revolution Medicines IncCOM · shares −2.9% · price −3.5%	10.5%	10.5%	$180.8M	4.1M	−2.9%	$43.74	$45.35	−3.5%	−$6.7M
5	CrowdStrikeCL A · shares 0% · price +22.0%	8.5%	6.5%	$146.4M	427,895	0%	$342.16	$280.47	+22.0%	+$26.4M
6	Planet Labs PbcCOM CL A · shares 0% · price +81.2%	7.5%	3.9%	$129.0M	31.9M	0%	$4.04	$2.23	+81.2%	+$57.8M
7	UiPathCL A · shares 0% · price −0.7%	5.2%	4.9%	$89.4M	7.0M	0%	$12.71	$12.80	−0.7%	−$633,091
8	Dexcom IncCOM · shares 0% · price +16.0%	4.7%	3.8%	$80.6M	1.0M	0%	$77.74	$67.04	+16.0%	+$11.1M
9	Verve Therapeutics IncCOM · shares 0% · price +16.5%	4.1%	3.2%	$69.6M	12.3M	0%	$5.64	$4.84	+16.5%	+$9.9M
10	Tempus AICL A · shares 0% · price −40.4%	3.0%	4.8%	$52.4M	1.6M	0%	$33.76	$56.60	−40.4%	−$35.4M
11	Prime Medicine IncCOM · shares 0% · price −24.5%	2.6%	3.2%	$44.0M	15.1M	0%	$2.92	$3.87	−24.5%	−$14.3M
12	Vera Therapeutics IncCL A · shares 0% · price −4.3%	0.59%	0.58%	$10.2M	241,264	0%	$42.29	$44.20	−4.3%	−$460,813
13	Monte Rosa Therapeutics IncCOM · shares 0% · price +30.9%	0.59%	0.42%	$10.2M	1.5M	0%	$6.94	$5.30	+30.9%	+$2.4M
14	Beam Therapeutics IncCOM · shares 0% · price +1.2%	0.46%	0.43%	$8.0M	321,604	0%	$24.80	$24.50	+1.2%	+$96,481
15	Oscar Health IncCL A · shares 0% · price −36.6%	0.38%	0.55%	$6.5M	481,988	0%	$13.44	$21.21	−36.6%	−$3.7M
16	Relay Therapeutics IncCOM · shares 0% · price −41.8%	0.38%	0.60%	$6.5M	1.6M	0%	$4.12	$7.08	−41.8%	−$4.6M
17	Sana Biotechnology IncCOM · shares 0% · price −60.8%	0.27%	0.64%	$4.6M	2.8M	0%	$1.63	$4.16	−60.8%	−$7.1M
18	Dianthus Therapeutics IncCOM · shares 0% · price −20.4%	0.26%	0.31%	$4.5M	208,697	0%	$21.80	$27.38	−20.4%	−$1.2M
19	Lyell Immunopharma IncCOM · shares 0% · price −53.6%	0.22%	0.44%	$3.8M	5.9M	0%	$0.640	$1.38	−53.6%	−$4.3M
20	Tscan Therapeutics IncCOM · shares 0% · price −39.0%	0.19%	0.29%	$3.3M	1.1M	0%	$3.04	$4.98	−39.0%	−$2.1M
21	Desktop Metal IncCOM CL A · shares 0% · price −49.9%	0.15%	0.28%	$2.6M	1.1M	0%	$2.34	$4.67	−49.9%	−$2.6M
22	Foghorn Therapeutics IncCOM · shares 0% · price −49.3%	0.14%	0.25%	$2.4M	500,901	0%	$4.72	$9.31	−49.3%	−$2.3M
23	Barinthus Biotherapeutics PlADS · shares 0% · price +1.7%	0.11%	0.10%	$1.8M	1.5M	0%	$1.21	$1.19	+1.7%	+$30,273
24	Genedx Holdings CorpCOM · shares 0% · price +81.1%	0.10%	0.05%	$1.7M	22,711	0%	$76.86	$42.44	+81.1%	+$781,712
25	Autolus Therapeutics PlcSPON ADS · shares 0% · price −35.3%	0.10%	0.14%	$1.6M	698,262	0%	$2.35	$3.63	−35.3%	−$893,775
	Total · 40 positions	100%		$1.72B						+$84.3M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q3 2024 to Q4 2024: 38 stocks held throughout, up $84.3M (+5.2%).

Freshworks Inc+$76.0M+41%
Planet Labs Pbc+$57.8M+81%
Gitlab Inc+$29.3M+9%
CrowdStrike+$26.4M+22%
Dexcom Inc+$11.1M+16%
Revolution Medicines Inc−$6.7M−4%
Sana Biotechnology Inc−$7.1M−61%
Prime Medicine Inc−$14.3M−25%
Tempus AI−$35.4M−40%
Arm Holdings Plc−$38.5M−14%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗